Trevi Therapeutics has announced significant milestones in its clinical programs for Haduvio (nalbuphine), an investigational therapy aimed at treating chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC). 4 October 2024
Paris-based asset manager Kurma Partners has raised 140 million euros ($154 million), successfully completing the first closing of Biofund IV 4 October 2024
Singapore’s Agency for Science, Technology and Research (A*STAR) and US biotech incubator Flagship Pioneering have agree to collaborate on advancing health and sustainability outcomes in Singapore and the broader Asia Pacific region. 4 October 2024
The US Food and Drug Administration (FDA) has removed the partial clinical hold on delpacibart etedesiran (del-desiran/AOC 1001), an investigational treatment designed to address the root cause of myotonic dystrophy type 1 (DM1), under development by US biotech Avidity Biosciences . 4 October 2024
Caliway Biopharmaceuticals has successfully completed its initial public offering, raising NT$6.4 billion ($206 million), the largest IPO in Taiwan's biotech industry to date. 3 October 2024
US clinical-stage biotech Arcus Biosciences has entered into a clinical trial collaboration with AstraZeneca on renal cancer treatments. 3 October 2024
PeptiDream says that its wholly-owned PDRadiopharma subsidiary has entered into a strategic partnership with French nuclear medicines firm Curium. 3 October 2024
Shares of UK drug developer Hemogenyx Pharmaceuticals rose as much as 9% and closed up 5.9% at 1.70 pence yesterday on the news of a further investment from Prevail Partners. 3 October 2024
UK-based biotech Resolution Therapeutics has announced the completion of a £63.5 million ($76.8 million) series B financing round led by Syncona. 3 October 2024
Liquidia Corporation and Pharmosa Biopharm have amended the current exclusive licensing agreement for the development and commercialization of L606. 3 October 2024
Timing can be crucial in biotech, and any company that can help optimize radiopharmaceuticals to fight cancer is likely to a hot property right now, given the recent popularity of the field among investors and drugmakers. 2 October 2024
UK-based biotech LoQus23 Therapeutics has closed a £35 million ($43 million) series A financing round, led by Forbion, with support from SV Health Investors' Dementia Discovery Fund and Novartis Venture Fund. 2 October 2024
Privately-held UK biotech Curve Therapeutics today announced the further strengthening of its leadership team with the appointments of Andre Hoekema as chairman of the board and Cora Griffin as head of business development. 2 October 2024
NK:IO, a London startup developing a cell therapy for treating solid tumors, has announced the appointment of a permant chief executive and the finalization of a seed funding round. 2 October 2024
Spanish epigenetics firm Oryzon Genomics has announced the receipt of the official meeting minutes from a recent End-of-Phase II meeting for vafidemstat in borderline personality disorder (BPD) with the US Food and Drug Administration (FDA). 2 October 2024
Halda Therapeutics, a US biotech company advancing cancer treatments, announced the appointment of Christian Schade as president and chief executive. 1 October 2024
Shares in CRISPR genome-editing biopharma company Caribou Biosciences were worth 37% more at mid-morning Friday than they were at Wednesday’s close. 13 May 2022
California, USA-based biotech BridgeBio Pharma has had a busy couple of days, first signing a mega-million-dollar deal with Bristol Myers Squibb and then selling a priority voucher. 13 May 2022
Swedish rare disease specialist Hansa Biopharma today revealed that the Swiss Agency for Therapeutic Products (Swissmedic) has granted time-limited market approval for Idefirix (imlifidase) for adult patients with a positive cross-match against an accessible organ from a deceased donor. 13 May 2022
Belgium’s cell therapy developer Bone Therapeutics (Euronext: BOTHE) today announced it has entered into a non-binding term sheet and exclusive discussions for a period of three months with the shareholders of Medsenic. 12 May 2022
Shares of German biotech Evotec closed up 14.4% at 24.17 euros on Tuesday, after it revealed it has extended and expanded its partnership with Bristol Myers Squibb in targeted protein degradation, originally signed in 2018. 11 May 2022
Armed with a pile of cash from its enormous successes with both a COVID-19 vaccine and antiviral treatment, US pharma giant Pfizer today announced the largest M&A deal so far this year in the biopharma sector. 10 May 2022
Swiss biotech Idorsia’s shares were up 1.4% at 13.71 francs by early afternoon today, having initially dropped to 13.26 francs, despite announcing disappointing Phase IIa results for its ACT-539313, a selective orexin-1 receptor antagonist. 10 May 2022
Denmark-based vaccine developer Bavarian Nordic saw its share drop more than 9% to 120.55 kroner by close of trading today on news that Johnson & Johnson subsidiary Janssen had terminated certain collaboration and license agreements. 9 May 2022
Swiss antibody-drug conjugate specialist ADC Therapeutics today announced that Chris Martin has stepped down as chief executive of the company. 9 May 2022
Shares of German biotech BioNTech were up 2.3% at $139.83 in pre-market New York trading, as the company reported financial results for the three months ended March 31, 2022. 9 May 2022
Myovant Sciences and Pfizer on Friday announced today that the US Food and Drug Administration has extended the review period for the supplemental New Drug Application (sNDA) for Myfembree (relugolix 40mg, estradiol 1mg, and norethindrone acetate 0.5mg) for the management of moderate to severe pain associated with endometriosis. 9 May 2022
Enthera Pharmaceuticals, a privately-held Italian biotech developing biologics for selected autoimmune conditions based on the discovery of an apoptosis pathway, has named Aled Williams chief executive. 6 May 2022
Sino-American biotech BeiGene has announced that the China National Medical Products Administration (NMPA) has granted conditional approval of Blincyto (blinatumomab) for injection for the treatment of pediatric patients with relapsed or refractory (R/R) CD19-positive B-cell precursor acute lymphoblastic leukemia (ALL). 6 May 2022
Privately-held Dutch biotech Byondis has entered into a license and collaboration and a supply agreement with medac GmbH, a privately owned pharmaceutical company based in Germany. 5 May 2022
Singapore-based Juniper Biologics and privately-held Swiss drugmaker Helsinn Group have signed an exclusive license agreement to develop and commercialize infigratinib (INN) in Australia, New Zealand, Southeast Asia and certain markets in the Middle East and Africa . 4 May 2022
US biotech companies Dragonfly Therapeutics and Gilead Sciences have announced a collaboration designed to advance a number of Dragonfly's novel natural killer (NK) cell engager-based immunotherapies for oncology and inflammation indications. 3 May 2022
Chinese biotech Hutchmed on Monday announced that the US Food and Drug Administration has issued a Complete Response Letter (CRL) regarding the New Drug Application (NDA) for surufatinib for the treatment of pancreatic (pNETs) and extra-pancreatic (non-pancreatic, epNETs) neuroendocrine tumors (NETs). 3 May 2022
Central nervous system (CNS) specialist Axsome Therapeutics expects to receive a complete response letter (CRL) from the FDA due to the recently revealed chemistry, manufacturing, and control (CMS) issues identified during the FDA’s review of its new drug application for AXS-07 (rizatriptan and meloxicam), for the acute treatment of migraines. 29 April 2022
Canada-based biotech Zymeworks late yesterday confirmed it has received an unsolicited, non-binding proposal from All Blue Falcons FZE (ABF) and its affiliates to purchase the company for $10.50 per share in cash, or some $773 million in total. 29 April 2022